open access

Vol 25, No 4 (2018)
Original articles — Interventional cardiology
Published online: 2017-12-01
Get Citation

Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system

Andreas S. Triantafyllis, Johan Bennett, Efstathios Pagourelias, Keir McCutcheon, Tom Adriaenssens, Peter R. Sinnaeve, Walter Desmet, Christophe Dubois
DOI: 10.5603/CJ.a2017.0141
·
Pubmed: 29240962
·
Cardiol J 2018;25(4):470-478.

open access

Vol 25, No 4 (2018)
Original articles — Interventional cardiology
Published online: 2017-12-01

Abstract

Background: To evaluate long-term clinical outcomes after treatment of complex bifurcation lesions with the AXXESS dedicated self-expanding biolimus A9-eluting bifurcation stent.
Methods: Between 2004 and 2013, 123 patients with complex bifurcation lesions were treated in a single-center with the AXXESS stent in the proximal main vessel (MV) and additional drug-eluting stents in branches when required. Median follow-up was 5 years. Primary endpoint was the rate of major adverse cardiac events (MACE). Secondary endpoints included MACE components (cardiac death, non-periprocedural clinical myocardial infarction [MI], target lesion revascularization [TLR] and definite/probable stent thrombosis [ST]) as well as all-cause death, target vessel revascularization (TVR) and non-TVR.
Results: During follow-up, 11 (8.9%) patients experienced a MACE, of whom 2 (1.6%) suffered cardiac death, 2 (1.6%) had a non-periprocedural clinical MI requiring TLR, and 7 (5.7%) underwent elective TLR. No definite/probable ST was observed. All-cause death occurred in 9 (7.3%) patients, TVR in 11 (8.9%) and non-TVR in 11 (8.9%). Patients treated for left main (LM) bifurcation lesions were more likely to experience MACE than non-LM bifurcation lesions (25% vs. 6.5%, p = 0.04).
Conclusions: Percutaneous revascularization of complex bifurcation lesions with the AXXESS stent is safe and provides excellent long-term results, especially in non-LM lesions.

Abstract

Background: To evaluate long-term clinical outcomes after treatment of complex bifurcation lesions with the AXXESS dedicated self-expanding biolimus A9-eluting bifurcation stent.
Methods: Between 2004 and 2013, 123 patients with complex bifurcation lesions were treated in a single-center with the AXXESS stent in the proximal main vessel (MV) and additional drug-eluting stents in branches when required. Median follow-up was 5 years. Primary endpoint was the rate of major adverse cardiac events (MACE). Secondary endpoints included MACE components (cardiac death, non-periprocedural clinical myocardial infarction [MI], target lesion revascularization [TLR] and definite/probable stent thrombosis [ST]) as well as all-cause death, target vessel revascularization (TVR) and non-TVR.
Results: During follow-up, 11 (8.9%) patients experienced a MACE, of whom 2 (1.6%) suffered cardiac death, 2 (1.6%) had a non-periprocedural clinical MI requiring TLR, and 7 (5.7%) underwent elective TLR. No definite/probable ST was observed. All-cause death occurred in 9 (7.3%) patients, TVR in 11 (8.9%) and non-TVR in 11 (8.9%). Patients treated for left main (LM) bifurcation lesions were more likely to experience MACE than non-LM bifurcation lesions (25% vs. 6.5%, p = 0.04).
Conclusions: Percutaneous revascularization of complex bifurcation lesions with the AXXESS stent is safe and provides excellent long-term results, especially in non-LM lesions.

Get Citation

Keywords

complex bifurcation lesions; dedicated stents; AXXESS stent

About this article
Title

Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system

Journal

Cardiology Journal

Issue

Vol 25, No 4 (2018)

Pages

470-478

Published online

2017-12-01

DOI

10.5603/CJ.a2017.0141

Pubmed

29240962

Bibliographic record

Cardiol J 2018;25(4):470-478.

Keywords

complex bifurcation lesions
dedicated stents
AXXESS stent

Authors

Andreas S. Triantafyllis
Johan Bennett
Efstathios Pagourelias
Keir McCutcheon
Tom Adriaenssens
Peter R. Sinnaeve
Walter Desmet
Christophe Dubois

References (25)
  1. Stankovic G, Lassen JF, Hildick-Smith D, et al. The EuroIntervention coronary bifurcation treatment supplement. EuroIntervention. 2015; 11 Suppl V: V9–11.
  2. Behan MW, Holm NR, Curzen NP, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv. 2011; 4(1): 57–64.
  3. Dubois C, Bennett J, Dens J, et al. COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. EuroIntervention. 2016; 11(13): 1457–1467.
  4. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol. 2005; 46(8): 1446–1455.
  5. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003; 108(14): 1701–1706.
  6. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007; 115(18): 2435–2441.
  7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17): 2126–2130.
  8. Lefèvre T, Chevalier B, Louvard Y. Is there a need for dedicated bifurcation devices? EuroIntervention. 2010; 6 Suppl J: J123–J129.
  9. Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention. 2013; 9(5): 573–581.
  10. Hasegawa T, Ako J, Koo BK, et al. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv. 2009; 73(1): 34–41.
  11. Miyazawa A, Ako J, Hassan A, et al. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial. Catheter Cardiovasc Interv. 2007; 70(7): 952–957.
  12. Dubois CL, Wijns W. The AXXESS™ self-expanding biolimus A9™ eluting stent system for coronary bifurcation lesions. EuroIntervention. 2010; 6 Suppl J: J130–J134.
  13. Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344–2351.
  14. Medina A, Lezo JS, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol. 2006; 59(2): 183.
  15. Bennett J, Dubois C. Coronary bifurcation lesions: is less more? J Thorac Dis. 2016; 8(10): E1351–E1354.
  16. Chen L, Fan L, Luo Y, et al. Ex vivo mono-ring technique simplifies culotte stenting for treatment of true bifurcation lesions: Insights from bench testing and clinical application. Cardiol J. 2016; 23(6): 673–684.
  17. Kern A, Gil RJ, Bojko K, et al. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience. Cardiol J. 2017; 24(6): 589–596.
  18. Bennett J, Adriaenssens T, Desmet W, et al. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial. Catheter Cardiovasc Interv. 2016; 88(6): 843–853.
  19. Verheye S, Buysschaert I, Grube E. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system. EuroIntervention. 2015; 11(8): 860–867.
  20. Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2016; 87(7): E248–E260.
  21. Stone G, Teirstein P, Meredith I, et al. Final five-year results of the platinum randomized trial comparing platinum chromium promus element and cobalt chromium promus/xience v everolimus-eluting stents in workhorse lesions. J Am Coll Cardiol. 2015; 65(10): A1733.
  22. Behan MW, Holm NR, de Belder AJ, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Eur Heart J. 2016; 37(24): 1923–1928.
  23. Maeng M, Holm NR, Erglis A, et al. Nordic-Baltic Percutaneous Coronary Intervention Study Group. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol. 2013; 62(1): 30–34.
  24. Kang SJ, Mintz GS, Kim WJ, et al. Changes in left main bifurcation geometry after a single-stent crossover technique: an intravascular ultrasound study using direct imaging of both the left anterior descending and the left circumflex coronary arteries before and after intervention. Circ Cardiovasc Interv. 2011; 4(4): 355–361.
  25. Murasato Y, Horiuchi M, Otsuji Y. Three-dimensional modeling of double-stent techniques at the left main coronary artery bifurcation using micro-focus X-ray computed tomography. Catheter Cardiovasc Interv. 2007; 70(2): 211–220.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl